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Rationale: Identiﬁcation of asthmatic subjects with low perception of dyspnea
(POD) that are at higher risk of hospitalization, near-fatal and fatal asthma could
improve their management.
Objective: Create a simple procedure that facilitate the recognition of low POD.
Methods: We enrolled near fatal asthma (NFA) subjects and a wide spectrum of non-
NFA subjects. Each subject was asked to stop breathing at end-expiration. Dyspnea
was assesssed by a modiﬁed Borg scale. To design the new index, we combined the
Borg score at the end of the voluntary breath-holding maneuver with the airway
limitation. The equation was as follows: FEV1/FVC%/(breath-holding time in
seconds/ﬁnal Borg score minus basal Borg score).
Results: Eleven NFA subjects (4 females) aged 21–73 yr and 55 non-NFA (14 severe,
18 moderate and 23 mild asthmatic subjects) completed the study. The threshold
value of the index that could predict POD iso12. The mean (7SD) of the new index
perception was signiﬁcantly lower in NFA group (n ¼ 11; 5.2173.59; vs. n ¼ 55;
13.67711.08; P ¼ 0.006). This threshold value had 100% sensitivity and it best
discriminated between mild and NFA groups. The negative likelihood ratio (when the
index X12) was zero. A result X12 represented an almost null probability of poor
POD.
Conclusion: The breath-holding test is simple and rapid. Its negative likelihood ratio
was zero. Accordingly, a test result of 12 or greater might exclude the probability of
poor perception of dyspnea in subjects with stable asthma.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Dyspnea perception in near-fatal asthma 247Introduction b-blockers, central depressants, or sedatives priorAn alteration in the ability of asthmatic patients to
perceive symptoms in their day-to-day life will
inﬂuence negatively in the management of asthma
due to an understimation of the symptoms sever-
ity.1–3 The awareness that early events portend an
increasingly severe condition is important for
timely treatment. This fact determines that, the
delay in instituting treatment is the single most
important factor contributing to death from asth-
ma.4 In this regard, a reduced chemosensitivity to
hypoxia and blunted perception of dyspnea during
resistive loading in subjects that had had a near
fatal asthma attack (NFA) was conﬁrmed by Kikuchi
et al.2 This is also, supported by a study in children
with a history of life threatening asthma that had a
signiﬁcantly decreased slope in their resistive load
magnitude estimation curve.5 More recently, Ma-
gadle and colleagues prospectively conﬁrmed that
asthmatic subjects with low perception of dyspnea
(POD) are at higher risk of hospitalization, near-
fatal and fatal asthma.6 All of these ﬁndings
pointed to perception as being a key factor in the
overall management of asthma.
Breath-holding time has been applied to evaluate
the control of breathing and the sensation of
experimentally induced dyspnea.7,8 It was hypothe-
sized that those patients who have experienced an
NFA attack should report a lower perception of
dyspnea under other conditions, speciﬁcally those
related to breath-holding maneuver, compared to
non-NFA asthma patients. The breath-holding man-
euver has been also used to detect the inﬂuence of
emotion on breathlessness in participants with
asthma.9
Accordingly, the main aim of the present study
was to create a perception index by assessing the
perception of dyspnea during the breath-holding
test in subjects with asthma.Methods
Subjects
Outpatient asthmatic subjects attending the center
were considered to participate. Subjects with prior
NFA, whom during the previous 12 months had
exacerbations were included. Near fatal event was
deﬁned as follows: orotracheal intubation due to
respiratory arrest during an asthma attack or acute
respiratory acidosis with hypercapnia 445mmHg.
None of the subjects had glotic dysfunction
syndrome, aspirin-induced asthma or had receivedto NFA. The control group included non-NFA
subjects that was classiﬁed according to WHO/
NHLBI report.10 None of the subjects had a history
of other respiratory disease than asthma, nor did
they use any other pulmonary medications than
inhaled corticosteroids, short- and long-acting b2
agonists. All subjects were nonsmokers or ex-
smokers (for more than 12 months, with less than
5 pack-yr). They speciﬁcally refrained for receiving
sedatives, CNS depressants, thyroid hormones, and
progestational treatment. The subjects were stu-
died during a clinically stable period.
None of the subjects had experienced an
exacerbation or a respiratory infection or need to
increase their treatment for at least 4 weeks. All
the treatments were withheld for 12 h and short-
and long-acting bronchodilators for 6 and 24 h,
respectively before each visit.Measurements
Self administered asthma quality of life question-
naire (AQLQ) was completed.11 After a 10min rest,
arterial oxyhemoglobin saturation was measured
with a pulse oximetry (BCI International, Wauke-
sha, WI). Then, each subject was asked ‘‘How does
your asthma feel right now?’’ and Which is the level
of your dyspnea? using a modiﬁed Borg scale (from 0
to 10) to take a basal rate of respiratory sensa-
tion.12 Immediately after, the breath-holding test
was explained. The subject was asked to stop
breathing at end-expiration and to hold his or her
breath with a nose clip for as long as possible
without encouragement, while looking to the
modiﬁed Borg scale. The end-expiration that should
correspond to FRC was determined by observing the
pattern of tidal breathing during at least 30 s. The
breath-holding maneuver was repeated a maximum
of 3 occasions separated by at least 2min if there
was410% difference in time between the ﬁrst and
second test. The total breath-holding time was
measured with a chronograph. The intensity of any
discomfort was marked with the modiﬁed Borg
scale (10 ¼ maximal discomfort) just at the break-
ing point that also deﬁned the end of breath-
holding maneuver. The test with the longer
voluntary breath holding was selected for analysis.
The greater fall in oxygen saturation during the test
was registered.
The equation that was applied to calculate the
new index is as follows:
FEV1/FVC%/(breath-holding time in seconds/ﬁnal
Borg score minus basal Borg score). The rationale
for the above equation was sustained in that the
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limitation related to low dyspnea perception.12
Then, we put breath-holding time in the denomi-
nator because we assumed that the longer the
holding time, the lower the dyspnea perception.8
Finally, we divided breath-holding time by the
difference in Borg score because a minor Borg score
difference may indicate poor symptoms percep-
tion, resulting in a lower index. In other words, the
lower the index was, the lower the symptoms in
near fatal asthma is o12. This threshold value was
selected because it had 100% sensitivity and best
discriminated between mild and NFA groups and it
was conﬁrmed by the receiver operating character-
istics (ROC) curves analysis.
Spirometry was performed with Datospir-200
(SibelMeds; Barcelona, Spain) and predicted va-
lues were obtained from Morris et al.13
Histamine challenge test was only performed in
the group of subjects who had suffered a NFA event
using the method of tidal breathing.14 The intensity
of any discomfort was marked with the modiﬁed
Borg scale immediately before each FEV1 measure-
ment. The perception score at the 20% fall in FEV1
(PS20) was determined by interpolation of the two
last perception scores. The slope and intercept of
the regression of Borg score and the percent fall
FEV1 were calculated for each subject.
The study was approved by the institutional
research committee, and each subject gave in-
formed consent to participate in the study.Statistical analysis
The total breath-holding time was deﬁned as the
time from the command of breath holding to the
breaking point.8 Unless otherwise stated, data are
expressed as mean (SD). Differences between
groups were assessed with one way analysis of
variance and all pairs with Tukey Kramer multiple
comparisons test if Po0.05 and if the Bartlett’s
test for homogeneity of variances was not signiﬁ-
cant. When variances were not homogeneous,
Kruskal–Wallis nonparametric ANOVA test and
Dunn’s multiple comparisons test was done.
Nonparametric unpaired Student’s t-test was
used to compare normally distributed variables,
and the Mann–Whitney U test was used for other
variables. Differences were assessed with two sided
tests, with an a level of 0.05. Spearman rank
correlation was used to test the relationship
between variables. A value of Po0.05 was ac-
cepted as indicating a statistically signiﬁcant
difference.A true positive result was deﬁned as occurring
when a patient’s index predicted low perception
(o12) and the suject actually belong to NFA group.
A true negative result as occurring when the index
predicted belonging to mild asthma group (X12)
and the subject actually belong to this group. A
false positive result as occurring when the index is
o12 in mild asthma and a false negative result
when the index is X12 and the subject is included
in the NFA group. The reproducibility of the test
according to Bland and Altman15 was randomly
assessed in 9 NFA and 9 non-NFA subjects by
measuring twice at least 15 days apart. The
positive and negative likelihood ratios of the test
results were calculated to assess the performance
in diagnosing the target disorder.Results
Three NFA patients were not enrolled in the study;
one due to pregnancy, other could not stop b
agonists at least 6 h before the challenge test and
the last one denied to participate. Two subjects of
the non-NFA group refused to participate. Eleven
near fatal asthma subjects (4 females) aged 21–73
year completed the study. Nine of them had
required orotracheal intubation due to respiratory
arrest during an asthma attack. The other two
patients had acute respiratory acidosis with
pH ¼ 7.26; PaCO2 ¼ 56mmHg; base excess ¼ 3
and pH ¼ 7.28; PaCO2 ¼ 58mmHg and base ex-
cess ¼ 2, respectively. The distribution according
to WHO/NHLBI10 categories of the 55 non-NFA
subjects was as follows: 23 patients (15 females)
as mild persistent or intermittent, 18 subjects as
moderate (8 females) and 14 (10 females) as severe
asthma. Table 1 shows the general characteristics
of the 4 groups. Mild asthmatic subjects were
younger than severe and NFA groups (Po0.05). The
median time elapsed since the near fatal event was
12.0 (95% CI ¼ 7.8–48.5) months. The history of
asthma in years was signiﬁcantly longer in NFA and
severe groups than in mild asthma group (Po0.05).
The mean FVC and FEV1 in liters were not
signiﬁcantly different between Mild and NFA
groups. Both variables, FVC and FEV1 of the severe
group were lower than the means of the other 3
groups. Means of FEV1% predicted
13 were signiﬁ-
cantly different between the groups with the
exception of NFA vs. moderate group. The mean
FEV1% pred of non-NFA subjects (n ¼ 55;
mean ¼ 75.4721.1) was similar to NFA subjects
(74.9712.6; P ¼ 0.68). The means of FEV1/FVC%
were different between severe vs. mild and
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Figure 1 Reproducibility of the test. Differences be-
tween two separated measurements of the new index;
and the means of both measurements were plotted. All
the differences were less than twice the SD of the mean
difference (10.98); n ¼ 18; mean difference ¼ 0.467
5.49. Y-axis (differences) denotes differences between
repeat measurements of the new index. X-axis (differ-
ences) denotes means of replicate measurements of the
new index.
Table 1 Subject characteristics.
Near fatal Severe Moderate Mild
Male/female 7/4 4/10 10/8 8/15
Age (yr) 46.3 (16.8) 46.4 (17.5) 35.22 (13.3) 30.4 (12.9)
Yrs of asthma 31.4 (16.1) 30.1 (13.4) 18.3 (13.2) 17 (14)
FEV1 (L) 2.34 (0.86) 1.34 (0.69) 2.38 (0.46) 2.97 (0.86)
FEV1% pred 75 (13) 48.1 (13.7) 75.6 (15.1) 91.9 (7.5)
FVC (L) 3.4 (1.14) 2.18 (1.05) 3.46 (0.66) 3.92 (1.1)
ICS dose 945.5 (465.5) 571.4 (601.8) 347.4(338.9) —
AQLQ 5.5 (1.2) 5.11 (1.27) 5.12 (1.34) 5.97 (1.26)
New perception
Index 5.21 (3.59) 6.43 (4.22) 11.45 (7.97) 19.68 (12.91)
Pulse rate 72.5 (4.7) 78.5 (16.0) 74.9 (6.0) 75.6 (8.4)
Percent fall O2 sat 4.1 (4.1) 4.0 (1.6) 4.4 (4.5) 2.6 (1.9)
Means (SD). See the text for statistical differences between groups.
Dyspnea perception in near-fatal asthma 249moderate (ANOVA; Po0.0001. Bartlett’s ¼ 0.98).
There was no difference in AQLQ between groups
despite the grading of severity. The % fall in O2
saturation at the end of the test was similar as well
as the basal pulse rate (Table 1). Nine NFA, 6
severe, and 3 moderate asthmatic subjects re-
peated the test within 2 and 12 weeks apart for
testing reproducibility. The calculated coefﬁcient
of repeatability was: 10.98; that is twice the
standard deviation of the differences of the 2
measures (5.49). The mean difference was 0.46 and
according to Bland and Altman15 it was not
signiﬁcantly different from zero. All the differences
were less than 10.98; then the index could be
considered as reproducible. Figure 1 shows the plot
of pairs of measurements according to Bland and
Altman.15
Comparisons of basal and ﬁnal Borg scores
between groups were not signiﬁcantly different.
The unpaired t test showed that the mean breath-
holding time of the NFA group was signiﬁcantly
longer than the mean of the non-NFA group
(34.46713.02; n ¼ 11 versus 24.1179.76; n ¼ 55;
P ¼ 0.0035); but the likelihood ratios (1.6 and 0.2)
indicated a poor diagnostic accuracy for altered
POD. The mean time of breath-holding was only
different between NFA and moderate groups
(ANOVA P ¼ 0.036 and Tukey Kramer Po0.05;
Table 2). None of the means of the perception
index components were statistically different be-
tween mild and NFA groups. The mean of the
new index perception was signiﬁcantly higher in
mild asthma group in comparison with near fatal
asthma and severe groups (Kruskal Wallis ANOVA
test ¼ Po0.001). When comparing NFA versus non-
NFA subjects, the new index perception was
signiﬁcantly lower in NFA group (5.2173.59; vs.13.67711.08, n ¼ 55; P ¼ 0.006). The threshold
value selected for predictive index of low breath-
lessness perception was 12 (if a subject had an
index value o12, he was considered as hypoper-
ceiver). The sensitivity of this index was 1.00;
speciﬁcity was 0.44 and the negative predictive
value was 1.00 for discriminating between non-NFA
(n ¼ 55) and near fatal asthma group. The area
under the ROC curve for the new index, which
summarizes the performance of that index in
detecting poor POD was 0.76 (standard
error ¼ 0.089) for the set derived from the data
on 55 non-NFA and 11 NFA subjects. The positive
likelihood ratio was 1.77 and the negative like-
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Table 2 Components of the new index.
Near fatal Severe Moderate Mild
Basal Borg score 1.41 (1.41) 2.0 (2.08) 1.28 (1.76) 0.57 (1.41)
Final Borg score 3.91 (1.97) 4.29 (2.56) 4.67 (2.52) 6.0 (2.52)
FEV1/FVC%
a 68.6 (9.0) 60.9 (8.2) 69.2 (8.0) 75.9 (8.7)
BH in secondsb 34.5 (13.0) 24.9 (8.6) 23.2 (10.5) 24.3 (10.2)
New perception
Index 5.21 (3.59) 6.43 (4.22) 11.45 (7.97) 19.68 (12.91)
Means (SD).
aFEV1/FVC% severe vs. moderate ¼ Po0.05. Severe vs. mild ¼ Po0.001.
bBH ¼ breath-holding test. BH time NFA vs. moderate Po0.05.
Figure 2 Receiver operating characteristic (ROC) curve
analysis for the index, generated by plotting the
proportion of true positive results (sensitivity) against
the proportion of false positive results (1-speciﬁcity) for
each value of the new index including the 23 mild
asthmatic subjects and 11 near fatal asthma subjects.
The area under the curve is expressed in the box as the
proportion of the total area of the graph.
L.J. Nannini et al.250lihood ratio (indexX12) was zero. In other words, a
test result lower than 12 was 1.77 times as likely to
have poor POD. Importantly, a result X12 gener-
ated an almost null probability of poor POD. When
the set of data for calculating the area under the
ROC curve was mild asthma group and NFA group,
the AUC was 0.89570.067 (Fig. 2). There was a
signiﬁcant correlation between the new index and
FEV1% pred (n ¼ 66, r ¼ 0.41; Po0.001) but it did
not correlate with age, history of asthma, AQLQ,
budesonide dose, FVC and time elapsed since the
NFA event.
The mean log Pc20 FEV1 histamine was 0.0977
0.61mg/ml (geometric mean Pc20 ¼ 0.80mg/ml;
range ¼ 0.05–4.74). The geometric mean PS20 in
Borg units was 2.53 (range ¼ 0–5.98) while the
mean Borg score at the end of the histamine testwas 3.2771.9. The mean slope and mean intercept
of the regression of Borg score/percent fall FEV1
were 0.06270.065 and 1.2871.18, respectively.
The difference between ﬁnal Borg score and post-
saline solution Borg score was 1.2671.44. There
was neither correlation between PS20FEV1 in Borg
units and the new index (r ¼ 0.36; P ¼ 0.3;
n ¼ 11) nor between slope and intercept with
new index (r ¼ 0.27 and 0.07; P: NS).Discussion
The present study introduced a new index to rule
out low perception of dyspnea in asthma. Until
now, no reliable predictive equation or simple
screening tool had been developed to identify
asthmatic patients with low POD. This index had a
sensitivity and a negative predictive value of 100%
for near fatal asthma group when a threshold o12
was applied. The negative likelihood ratio was zero
and this ratio excluded the presence of low POD
when the index result was X12.
This new index has some interesting features.
Firstly, it was intrasubject reproducible, simple and
rapid. It could be easily calculated and readily
available. It just required a spirometer, a chron-
ometer and a modiﬁed Borg dyspnea scale from
zero to 10 units. This index might be used to rule
out poor perception of dyspnea. Poorly perceived
asthma is one of the main factors associated with
death from asthma.16
The ROC curve provided a powerful means of
assessing a test’s ability to discriminate between
two groups of patients, with the advantage that the
analysis did not depend on the threshold value
selected. The area under the ROC curve was quite
large (0.895) between mild and NFA groups and this
analysis circumvented the main problem inherent
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namely, dependence on the threshold value that
was selected. The negative likelihood ratio equal to
zero denoted that the probability of poor POD was
extremely low when the index was X12. Hypothe-
tically, this index should be prospectively assessed
as a marker of high risk by correlating with the lack
of activation of cortical neurons as it has been
studied using respiratory-related evoked potential
techniques.17 Diminished activation of cortical
neurons might be reﬂected by a low index result.
Unfortunately, breath-holding time alone showed
unsatisfactory likelihood ratios in order to change
the probability for diagnosing altered POD.
Diminished perception of dyspnea and airway
narrowing had a relevant role in treatment delay,
near fatal events, and death during acute severe
asthma. In this regard, Magadle and colleagues6
found in 2 years of follow up that 29 asthmatic
patients with poor perception of dyspnea (POD)
suffered 13 near-fatal attacks and six deaths. These
authors strongly recommended to measure POD at
least once in all asthmatic subjects with either
technique, the method of breathing against added
resistance or added threshold loads, or the metha-
choline/histamine bronchoprovocation test. Bijl-
Hoﬂand and colleagues showed that the histamine-
induced bronchoconstriction test identiﬁed more
patients as poorest perceivers compared to the
threshold loading test.18 Within the bronchoprovo-
cation test, many alternative indexes to PS20FEV1
have been described for detecting subjects with
poor POD or prone to near fatal asthma such as the
percentage fall in FVC/log Pc20FEV1,
19 the change
in Borg scale as the mathematical difference
between PS20 histamine and baseline dyspnea
20;
and the slope and intercept from linear regression
of Borg/% fall in FEV1
21 The simplest marker for NFA
was the FEV1o79% predicted or the FEV1/FVC ratio
of o75% that was recently published by Gelb
et al.22 We did not ﬁnd any difference in FEV1%
predicted between NFA group (n ¼ 11; 74.97
12.6%) and the rest of the population studied
(n ¼ 55; 75.4%721.2; P ¼ 0.68). In contrast the
new index perception in NFA group was signiﬁcantly
lower (5.2173.59) than in the rest of the subjects
(n ¼ 55; 13.67711.08; P ¼ 0.006). Other proce-
dures attempting to recognize poor POD and NFA
subjects has been published such as a Borg score
o6 at peak cycle exercise,23 and the failure of
inspiratory occlusion to elicit the P1 peak of the
respiratory-related evoked potentials that was
found in a subpopulation of children with prior
NFA.17 Davenport et al suggested that an altered
neural processing of inspiratory load information
could explain the failure in recognizing the airwayobstruction.17 Webster and Colrain24 investigated
the long latency evoked potentials and found a
markedly reduced respiratory and auditory P3
components in subjects with asthma compared
with the control group without asthma. They
sustained that a general sensory deﬁcit is involved
in the mechanism of perceptual processing in
asthmatic subjects.
Despite the fact that it is still not known whether
the altered POD is acquired or inherited, NFA
subjects should not be considered as having an
irreversible and inevitably lethal phenotype.25
Furthermore, there was some evidence that in-
haled corticosteroids and combined therapy might
improve symptoms perception.26,27
The new index was not statistically different
between severe, moderate and NFA subjects.
Undoubtedly, the best example of blunted percep-
tion was near fatal asthma1–3; but also a poor POD
might be found in other categories of asthmatic
patients. Importantly, poor perception of breath-
lessness was associated with: severity of asthma in
outpatients with different grading of asthma,28
particularly those with recurrent exacerbations29;
with elderly asthmatic patients,30 with long-stand-
ing airﬂow limitation,12 and during ICS dose
reduction.31 This strong relationship between se-
vere and long-standing airway obstruction with low
POD lend support the inclusion of the FEV1/FVC
ratio in this new index. Simultaneously, severity
became the major confounding factor of a low POD
index, such that we found similar index means in
NFA and severe group (Table 1), and by the other
way, mild asthma group showed the higher mean of
the new index perception.
Our study has some potential limitations. It was
not a case control trial, although there were no
signiﬁcant differences in the equation components
between NFA and mild asthma groups. The per-
ceived sensation of voluntary breath-holding is
somewhat different from symptoms during an
spontaneous asthma exacerbation. Killian and
colleagues suggested that in acute asthma, the
stimulation of free nerve endings in the airways
may cause an additional drive to breathe leading to
air hunger and breathlessness in the same way as a
rising PaCO2 due to holding one’s breath. These
symptoms were not discriminated, suggesting a
common mechanism as expected.32 We did not ﬁnd
a correlation between PS20 and FEV1 in Borg units
and the new index probably due to the fact that
these procedures could not comprise the different
aspects of the complex process of symptom
perception. The investigators that performed the
tests were aware of the patient condition and this
issue could have caused some bias. However, the
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of the study. Finally, as severity and long-standing
airﬂow limitation12,28,29 were intrinsically related
with loss of POD the new index might not be able to
discriminate poor perception from severe airway
obstruction.
Reduced awareness of methacholine/histamine-
induced bronchoconstriction was only described in
one of 3 studies of near fatal asthmatic patients.
Rufﬁn et al.,33 showed a mean value (SD) for the NFA
group (n ¼ 43), 0.8670.56mm/percent change in
FEV1, that was signiﬁcant less than for the non-NFA
asthmatic group, 1.1370.72mm/percent change in
FEV1, P ¼ 0.012. Boulet et al.34 found a mean PS20
FEV1 of 3.070.7 in 13 NFA subjects and 2.570.4 in
the control group. Turner and colleagues35 found no
difference between NFA and admitted patients
without NFA event. Salome et al.36 studied the
perception of airway narrowing in a large popula-
tion sample involving 697 adults who underwent
challenge testing with histamine. They found that
subjects with asymptomatic AHR did not differ
signiﬁcantly from subjects with current asthma
either in the mean fall in FEV1 (24% vs. 27%) or in
the median Borg score at the end of the challenge
(4 vs. 4). Our data from NFA subjects were: mean
fall in FEV1 ¼ 28% and the median Borg score was
also 4. Then, measurement of POD during histamine
challenge test was similar between our NFA group
and asymptomatic AHR subjects studied by Salome
et al.36 It was evident that there was no deﬁnite cut
off point to determine altered POD from the
histamine challenge test. Furthermore, since the
geometric mean Pc20 of the different series of NFA
was 0.23mg/ml,37 subjects received few histamine
doses and thus there were a few points to construct
the lineal regression Borg score/% fall FEV1 in order
to calculate the slope and intercept. These vari-
ables seemed to be more sensitive in detecting
changes in perception.18,21 Bijl-Hoﬂand et al.18
found that 25% of the patients with the poorest
perception value (assessed by bronchial provoca-
tion) had a slope of o0.4. Accordingly, the mean
slope of the regression Borg/% fall FEV1was 0.062 in
our NFA group, conﬁrming poor POD. But, this does
not mean that patients with a slope of o0.4 are
actually absolute poor perceivers.18 In this regard,
Salome et al.26 found a very low Borg/FEV1 slope
(0.09) in 35 non-NFA subjects that was indicating
poor POD, while their PS20 FEV1 was high (5.66),
suggesting good perception. All of these contra-
dictory results reinforced the fact that, there was
no gold standard or uniﬁed reference test result to
consider a subject as a poor perceiver or not.
In conclusion, the breath-holding test index was
simple, and readily available. According to thenegative likelihood ratio, the test result of 12 or
greater might exclude the probability of poor
perception of dyspnea in subjects with stable
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